Literature DB >> 27123077

Primary extragastrointestinal stromal tumor of the pleura: A case report.

Cai-Qing Zhang1, DE-Gan Lu1, Qing-Fa Liu1, Wei Xiao2.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumor of the gastrointestinal tract. The stomach and small intestine are the most common sites of occurrence. GISTs are mesenchymal neoplasms originating from the interstitial cells of Cajal (ICCs), and are characterized by positivity for cluster of differentiation (CD) 117, also known as proto-oncogene c-Kit. While the majority of GISTs develop in the alimentary tract, in rare cases they may also be found in extragastrointestinal tissues. This type of GIST is known as an extragastrointestinal stromal tumor (EGIST). Despite the fact that EGISTs have been reported in the mesentery, omentum and retroperitoneum, primary intrathoracic EGISTs, arising from the pleura or lungs, are rare. The patient presented in the current study was a 40-year-old man, who presented with a cough and pyrexia, with pleural effusion on the left side. Multiple nodules throughout the parietal pleura were identified by thoracoscopy and a diagnosis of primary GIST of pleura was established, since they were positive for CD117 and discovered on GIST-1 and there was no evidence of gastrointestinal tumors. Subsequently, the patient was administered with imatinib and had no signs of disease recurrence 2 years later.

Entities:  

Keywords:  biopsy; extragastrointestinal stromal tumors; pleura; thoracoscopy

Year:  2016        PMID: 27123077      PMCID: PMC4841089          DOI: 10.3892/ol.2016.4344

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Diagnosis of gastrointestinal stromal tumor (GIST) on transurethral resection of the prostate: a case report and review of the literature.

Authors:  Eleftherios Anagnostou; Dimosthenis Miliaras; Victor Panagiotakopoulos
Journal:  Int J Surg Pathol       Date:  2011-06-01       Impact factor: 1.271

3.  Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers?

Authors:  M J Ríos-Moreno; S Jaramillo; S Pereira Gallardo; A Vallejo; M Mora; A García-Escudero; J Amérigo; R González-Cámpora
Journal:  Pathol Res Pract       Date:  2011-12-24       Impact factor: 3.250

4.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.

Authors:  Kyung-Hee Kim; Scott D Nelson; Dong-Hoon Kim; Kyung Un Choi; Su Jin Kim; Kyueng-Whan Min; Ki-Seok Jang; Seung Sam Paik; Young-Ha Oh; Seoung Wan Chae; Jin Hee Sohn; Hong Joo Kim; Yong Kyun Cho; Byung Ik Kim; Dong Il Park; Chong Il Sohn; Sukjoong Oh; Seon Hyeong Choi; Yoon Jung Choi; Hee-Yeon Woo; Yong Lai Park; Se Jin Park; Sang Hyuk Lee; Seungho Ryu; Sung-Im DO; Guhyun Kang; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

6.  Modeling of stochastic behavior of pacemaker potential in interstitial cells of Cajal.

Authors:  Jae Boum Youm; Chae Hun Leem; Sung Ryul Lee; In-Sung Song; Hyoung Kyu Kim; Hye Jin Heo; Byung Joo Kim; Nari Kim; Jin Han
Journal:  Prog Biophys Mol Biol       Date:  2014-09-17       Impact factor: 3.667

7.  Primary extragastrointestinal stromal tumors: a clinicopathological and immunohistochemical study - a tertiary care center experience.

Authors:  R Patnayak; A Jena; S Parthasarathy; P D Prasad; M K Reddy; A K Chowhan; N Rukamangadha; B V Phaneendra
Journal:  Indian J Cancer       Date:  2013 Jan-Mar       Impact factor: 1.224

8.  Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes.

Authors:  Tadashi Terada
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Clinicopathological and treatment analysis of 13 extragastrointestinal stromal tumors of mesentery and retroperitoneum.

Authors:  Nida Iqbal; Atul Sharma; Naveed Iqbal
Journal:  Ann Gastroenterol       Date:  2015 Jan-Mar
View more
  3 in total

1.  Extragastrointestinal stromal tumour of the lesser omentum: A case report and literature review.

Authors:  I E Katsoulis; A Tzortzopoulou; P Tziakou; N Arnogiannaki; I Kostoglou-Athanassiou; G Lypas; I G Karaitianos
Journal:  Int J Surg Case Rep       Date:  2017-06-08

2.  A correlation research of Ki67 index, CT features, and risk stratification in gastrointestinal stromal tumor.

Authors:  Huali Li; Gang Ren; Rong Cai; Jian Chen; Xiangru Wu; Jianxi Zhao
Journal:  Cancer Med       Date:  2018-08-19       Impact factor: 4.452

3.  Giant gastric stromal tumor mimicking as a posterior mediastinal mass: A case report and literature review.

Authors:  Xiaonan Yin; Chaoyong Shen; Yuan Yin; Zhaolun Cai; Zhixin Chen; Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.